We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
- Authors
Kim, H K; Choi, I J; Kim, C G; Kim, H S; Oshima, A; Yamada, Y; Arao, T; Nishio, K; Michalowski, A; Green, J E
- Abstract
To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at P<0.05 (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the poor prognosis signature and are contained within identified genomic amplicons. The combined expression of three genes-MYC, EGFR and FGFR2-was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted P=0.017), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted P=0.026). Thus, combined expression of MYC, EGFR and FGFR2 is predictive of poor survival in CF-treated metastatic gastric cancer patients.
- Publication
The pharmacogenomics journal, 2012, Vol 12, Issue 2, p119
- ISSN
1473-1150
- Publication type
Journal Article
- DOI
10.1038/tpj.2010.87